Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CART in Relapsed/Refractory B-ALL
NCT03614858Phase 2Recruiting
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Sep 2017
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AUTO3 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.. Started Sep 2017; status: recruiting.
02
Drugs
AUTO3
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03614858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614858.